Physician profile
Ryan C Hafner
NPI 1548793326
$163,748.57
in general payments reported to CMS, 2019-2025
35 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $16K · 2022: $9,350 · 2023: $21K · 2024: $45K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $38K · Travel and Lodging: $18K · Food and Beverage: $5,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,758.75 |
| Consulting Fee | $37,860.00 |
| Travel and Lodging | $17,637.50 |
| Food and Beverage | $5,608.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $85,582.25 | 2021-2025 | Xeomin, Inbrija |
| Ipsen Biopharmaceuticals, INC | $53,506.68 | 2021-2025 | Dysport |
| Medtronic, INC. | $16,720.58 | 2021-2023 | Intellis Adaptivestim |
| Abbvie INC. | $4,886.86 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $1,426.86 | 2023-2025 | Iovera, Exparel, Zilretta |
| Merz North America, INC. | $156.19 | 2020 | |
| Horizon Therapeutics Plc | $154.49 | 2022-2023 | Uplizna |
| Argenx US, INC. | $152.23 | 2022 | |
| Merck Sharp & Dohme LLC | $124.46 | 2023 | Verquvo |
| Revance Therapeutics, INC. | $121.93 | 2024 | Daxxify |
| Ge Healthcare | $100.62 | 2022-2023 | |
| Biogen, INC. | $92.71 | 2022 | |
| Saol Therapeutics INC. | $76.27 | 2022 | |
| Lilly USA, LLC | $63.47 | 2022-2023 | Emgality, Reyvow |
| Amgen INC. | $52.80 | 2022-2023 | Aimovig |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $49.58 | 2022 | |
| Microtransponder, INC. | $43.60 | 2023-2025 | |
| Csl Behring | $39.00 | 2023 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $38.40 | 2022 | |
| Acadia Pharmaceuticals INC | $35.89 | 2023 | Nuplazid |
| Corium, LLC | $33.22 | 2023 | Adlarity |
| Mdd US Operations, LLC | $33.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.64 | 2022 | |
| Pfizer INC. | $27.54 | 2023 | |
| Banner Life Sciences, LLC | $24.46 | 2023 | |
| Ucb, INC. | $24.14 | 2022 | |
| Lundbeck LLC | $23.83 | 2023 | Vyepti |
| Neurocrine Biosciences, INC. | $18.62 | 2023 | Ongentys, Ingrezza |
| Bioventus LLC | $18.34 | 2023 | L300 Go System |
| Smith+Nephew, INC. | $18.33 | 2024 | Collagenase Santyl |
| Acorda Therapeutics, INC | $16.40 | 2022 | |
| Sumitomo Pharma America, INC. | $15.40 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $14.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.11 | 2022 | |
| Kyowa Kirin, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hafner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.